Juha K. Rantala
Turku, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 05, 2026
Pan-cancer ex vivo target evaluation of phosphodiesterase 3 A (PDE3A).
Journal: Journal of molecular medicine (Berlin, Germany)
Published: December 04, 2025
Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.
Journal: Communications medicine
Published: June 18, 2025
FANCD2 restrains fork progression and prevents fragility at early origins upon re-replication.
Journal: Nature communications
Published: February 06, 2025
LIMA1-alpha staining predicts curative intent surgery response in HPV negative head and neck cancer.
LIMA1-alpha staining predicts curative intent surgery response in HPV negative head and neck cancer.
Journal: EMBO molecular medicine
Published: October 21, 2024
Retraction Notice to: A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.
Journal: Molecular cell
Published: June 01, 2024
In-vitro assays for immuno-oncology drug efficacy assessment and screening for personalized cancer therapy: scopes and challenges.
Journal: Expert review of clinical immunology
Published: March 28, 2024
Assessment of targeted therapy opportunities in sinonasal cancers using patient-derived functional tumor models.
Journal: Translational oncology
Published: December 13, 2023
Defined extracellular matrix compositions support stiffness-insensitive cell spreading and adhesion signaling.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 16, 2023
Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients.
Journal: F1000Research
Published: October 06, 2023
Precision oncology using ex vivo technology: a step towards individualised cancer care?
Journal: Expert reviews in molecular medicine
Published: October 03, 2022
FBXL12 degrades FANCD2 to regulate replication recovery and promote cancer cell survival under conditions of replication stress.
Journal: Molecular cell
Published: June 16, 2022
Last Updated: 09/26/2026